Blog Posts
Innovations Advanced by M&A: A First-in-Class Therapy for Myasthenia Gravis
The 2020 acquisition of Momenta Pharmaceuticals by Johnson & Johnson (J&J) was critical to advancing IMAAVY (nipocalimab), a first-in-class therapy for generalized myasthenia gravis (gMG).
Life Sciences M&A Provides a Critical Path for Innovation Amid Declining Biotech Funding
As small and mid-sized biotech companies are facing increasing funding pressures, life sciences mergers and acquisitions (M&A) have emerged as an increasingly important mechanism to sustain innovation and advance new therapies.
PULSE Urges FTC, DOJ To Reconsider Policies that Deter Pro-Competitive Life Sciences M&A
In comments to the Department of Justice (DOJ)’s Anticompetitive Regulations Task Force, PULSE urged DOJ and Federal Trade Commission (FTC) officials to revisit antitrust policies that are deterring pro-competitive life sciences M&A.
Axios: M&A a “Life Raft” for Investment, Innovation in America’s Life Sciences Industry
Amidst greater market uncertainty and a severely constrained IPO environment, mergers and acquisitions (M&A) are serving as a critical “life raft” for investment, innovation and growth in America’s life sciences industry, reports Axios’ Katherine Davis in her recent article, “Biotechs search for buyers as runways end.”
PULSE Urges Trump Administration to Revisit HSR Rule, Ease Regulatory Burden on Pro-Competitive Life Sciences M&A
In response to the Office of Management and Budget’s recent Request for Information on Deregulation, PULSE urged federal regulators to revisit the latest changes to the Hart-Scott-Rodino (HSR) premerger notification rule.
PULSE Partners Return to Capitol Hill to Advocate for Pro-Competitive Life Sciences M&A
As part of PULSE’s efforts to engage policymakers around the unique and fundamental role of mergers and acquisitions (M&A) within the life sciences industry, PULSE partners made their way to Capitol Hill to emphasize how these critical partnerships are advancing new medicines to patients.
Life Sciences M&A Fuels Domestic Manufacturing
The U.S. life sciences industry is a key driver of economic growth and domestic manufacturing. American pharmaceutical manufacturers employ an estimated 291,000 employees, and for every one job in the pharmaceutical industry, four jobs are created in supporting...
M&A Fuels Innovation and Competition in Obesity Treatment
As the need for more effective and accessible obesity medicines grows, mergers and acquisitions (M&A) have emerged as a key strategy for life science companies of all sizes to accelerate innovation and competition to bring new treatment options to patients.
From Innovation to Economic Growth: The Role of M&A in Local Communities
M&A in America’s life sciences industry not only plays a critical role in bringing new breakthroughs to patients, but also strengthens state economies across the country. Life sciences M&A plays a pivotal role in fueling innovation, creating jobs and attracting long-term investment to local communities.
New PULSE Resource: Research Article – The Impact of Pharmaceutical M&A on Innovation
A new PULSE resource includes key insights from economists at Cornerstone Research on the the unique and fundamental role of mergers and acquisitions (M&A) in driving innovation across America’s biopharmaceutical industry.